Price: quote on request. Your total cost is quoted in writing per case.
We reply within one business day
Get my quote

Parkinson's disease: US-approved treatments and how Gulf families can access them

A plain guide for families in the Gulf, checked against US FDA labels, Gulf drug registers and published medical research.

Reviewed by the Reserve Meds clinical operations team on 17 October 2026.

Parkinson's disease: the short answer

The US FDA has approved six medicines on this page for Parkinson's disease, each for specific patients. Four of them are on at least one Gulf register we checked, so ask your hospital about local supply first. Otherwise the hospital can request a named-patient import. Reserve Meds is a digital health company. We do not diagnose or prescribe.

  • US FDA-approved medicines on this page: Vyalev, Crexont, Ongentys, Xadago, Gocovri and Nuplazid.
  • Gulf registration (checked 17 October 2026): see each medicine below.
  • Legal route: Local supply where listed; otherwise a named-patient import request filed by the treating hospital.
  • Price: Quote on request.

What is Parkinson's disease?

Parkinson's disease is a movement disorder that happens when nerve cells in the brain do not make enough dopamine. Symptoms begin gradually, often on one side of the body, and later affect both sides. They include trembling, stiffness, slow movement and poor balance and coordination.[1]

As the disease progresses, people may have trouble walking, talking or doing simple tasks, and may develop depression, sleep problems or swallowing difficulties. Some people develop hallucinations or dementia. Parkinson's usually begins around age 60 and is more common in men.[1, 2]

There is no specific test, so diagnosis is based on history and a neurological exam. There is no cure, but medicines can help symptoms a great deal, and surgery or deep brain stimulation can help in severe cases. In the US, medicines are approved for motor fluctuations, off episodes, dyskinesia and Parkinson's psychosis.[1, 3, 4]

Parkinson's disease in the Gulf

A review of Parkinson's disease in the Gulf countries noted a relatively low reported prevalence in the Saudi Al-Thugba study (27 per 100,000) and suggested that high rates of consanguinity may make familial cases more likely to be seen than elsewhere.[5]

US FDA-approved medicines for Parkinson's disease

Each medicine below is approved in the US for a specific group of patients. The wording summarizes the current US label. Your specialist decides whether any of them is right for the patient.

  • Vyalev (foscarbidopa/foslevodopa)
    FDA-approved for motor fluctuations in adults with advanced Parkinson's disease. It is a continuous infusion under the skin through a pump.[3]
    Gulf registers: Saudi Arabia: not found by brand name in the SFDA drugs list. Abu Dhabi: has an active code in the Abu Dhabi DoH drug code list. Checked 17 October 2026. UAE federal status, Kuwait, Qatar, Bahrain and Oman: not verified in a public register.[6, 7]
    Country guides: Saudi Arabia, UAE
  • Crexont (carbidopa and levodopa)
    FDA-approved for Parkinson's disease and some other forms of parkinsonism in adults. It is an extended-release capsule of carbidopa and levodopa.[8]
    Gulf registers: Saudi Arabia: not found by brand name in the SFDA drugs list. Abu Dhabi: not found by brand name in the Abu Dhabi DoH drug code list. Checked 17 October 2026. UAE federal status, Kuwait, Qatar, Bahrain and Oman: not verified in a public register.[6, 7]
    Country guides: Saudi Arabia, UAE, Kuwait, Qatar, Egypt, Turkey, India, Pakistan
  • Ongentys (opicapone)
    FDA-approved for an add-on to levodopa/carbidopa in patients with Parkinson's disease who have off episodes. It is a capsule.[9]
    Gulf registers: Saudi Arabia: not found by brand name in the SFDA drugs list. Abu Dhabi: has an active code in the Abu Dhabi DoH drug code list. Checked 17 October 2026. UAE federal status, Kuwait, Qatar, Bahrain and Oman: not verified in a public register.[6, 7]
    Country guides: Saudi Arabia, UAE, Kuwait, Qatar, Bahrain, Oman
  • Xadago (safinamide mesylate)
    FDA-approved for an add-on to levodopa/carbidopa in patients with Parkinson's disease who have off episodes. It is a tablet.[10]
    Gulf registers: Saudi Arabia: listed in the SFDA drugs list. Abu Dhabi: has an active code in the Abu Dhabi DoH drug code list. Checked 17 October 2026. UAE federal status, Kuwait, Qatar, Bahrain and Oman: not verified in a public register.[6, 7]
    Country guides: Saudi Arabia, UAE, Kuwait, Qatar, Bahrain, Oman, Egypt
  • Gocovri (amantadine)
    FDA-approved for dyskinesia in patients with Parkinson's disease receiving levodopa-based therapy, and as an add-on for off episodes. It is an extended-release capsule taken at bedtime.[11]
    Gulf registers: Saudi Arabia: not found by brand name in the SFDA drugs list. Abu Dhabi: not found by brand name in the Abu Dhabi DoH drug code list. Checked 17 October 2026. UAE federal status, Kuwait, Qatar, Bahrain and Oman: not verified in a public register.[6, 7]
    Country guides: Saudi Arabia, UAE, Kuwait, Qatar, Bahrain, Oman
  • Nuplazid (pimavanserin tartrate)
    FDA-approved for hallucinations and delusions associated with Parkinson's disease psychosis. It is taken by mouth.[4]
    Gulf registers: Saudi Arabia: not found by brand name in the SFDA drugs list. Abu Dhabi: has an active code in the Abu Dhabi DoH drug code list. Checked 17 October 2026. UAE federal status, Kuwait, Qatar, Bahrain and Oman: not verified in a public register.[6, 7]
    Country guides: Saudi Arabia, UAE, Kuwait, Qatar, Bahrain, Oman, India

How families in the Gulf can access these medicines

If the medicine is listed in your country. Ask your specialist and the hospital pharmacy about local supply first. A listing does not mean every hospital stocks the medicine, and another brand of the same medicine may also be registered, but local supply is usually the fastest route and you may not need us.

If it is not registered. The usual legal route is a named-patient request: the treating hospital, on your specialist's written request, asks the national regulator for permission to import the medicine for one patient, using the US FDA approval as the reference. In Saudi Arabia the SFDA Special Access Program guidance covers these requests; in Bahrain, NHRA Circular 41 of 2020 sets the procedure. Other Gulf countries have their own procedures, which the hospital pharmacy confirms.[12, 13] Once approval is in place, Reserve Meds arranges supply through a US-licensed pharmaceutical wholesale partner to the hospital pharmacy.

Who does what

  • Your treating specialist decides whether a medicine is right for the patient and writes the letter.
  • The hospital checks local supply, files any import request, and gives the treatment safely.
  • The national regulator decides whether to approve the import of a medicine that is not registered.
  • The manufacturer decides where its medicine can be supplied, especially for cell and gene therapies.
  • Reserve Meds helps organize records, coordinates US supply through our wholesale partner, shipping and updates to your family. We do not give medical advice.

Documents you will usually need

  • A letter from the treating specialist with the diagnosis, past treatments and why the medicine is being considered
  • Reports that confirm the diagnosis, such as laboratory, genetic, imaging or pathology results, translated into English where needed
  • Recent clinic notes and a list of current medicines
  • For a hospital import request: the prescription, the hospital's request form and the written consent of the patient or guardian
  • Proof of the US FDA approval and the US prescribing information (we can supply these)

We give you a written timeline estimate once we see the hospital file. The regulator, the treatment center and the manufacturer set their own timelines.

What treatment costs

Quote on request. Your total cost depends on the medicine, the dose, shipping, import steps and coordination. Your coordination fee is quoted in writing for your case before you commit. No hidden charges.

How Reserve Meds helps

Reserve Meds is a digital health company. Medicines are supplied through a US-licensed pharmaceutical wholesale partner. We help your doctor and hospital prepare the file, arrange US supply and temperature-controlled shipping once approval is in place, and keep your family updated. We coordinate access to FDA-approved medicines only. Investigational medicines are only available through a manufacturer's expanded-access program requested by the treating physician; we can explain that route, but we do not supply them.

Ask us about treatment for Parkinson's disease

Tell us the medicine, your country and a WhatsApp or phone number. We reply within one business day. On WhatsApp we usually reply the same day.

Include the country code, for example +966 or +971.
Message us on WhatsApp

No account needed. We reply within one business day. Your coordination fee is quoted in writing for your case before you commit. No hidden charges.

Frequently asked questions

Is there an FDA-approved treatment for Parkinson's disease?

Yes. The medicines on this page have US FDA approval for specific groups of patients: Vyalev, Crexont, Ongentys, Xadago, Gocovri and Nuplazid. The exact conditions are in each US label and are summarized above. Your specialist decides whether any of them fits.

Is Vyalev available in Saudi Arabia or the UAE?

Saudi Arabia: not found by brand name in the SFDA drugs list. Abu Dhabi: has an active code in the Abu Dhabi DoH drug code list. Checked 17 October 2026. UAE federal status, Kuwait, Qatar, Bahrain and Oman: not verified in a public register. A listing in Abu Dhabi does not show federal UAE status.

How can a family in the Gulf get Vyalev?

Ask the treating hospital about local supply first. If it is not available, the hospital can file a named-patient import request with the national regulator on your specialist's written request. Once approved, we arrange US supply to the hospital pharmacy.

How much does treatment cost?

Quote on request. Your total cost, including the medicine, shipping, import steps and coordination, is quoted in writing for your case before you commit. No hidden charges.

What is an off episode?

It is a period when Parkinson's symptoms return between doses because the medicine effect wears off. Ongentys and Xadago are US-approved add-ons for patients with off episodes.

Is there a cure for Parkinson's disease?

No. MedlinePlus explains there is no cure, but medicines can help symptoms a great deal, and surgery or deep brain stimulation can help some severe cases.

Sources for the last two answers: [9, 10] [1]

Sources

Checked on 17 October 2026. Labels, registers and regulator rules change. Your hospital pharmacy confirms the current position before filing.

  1. MedlinePlus (US National Library of Medicine): Parkinson's Disease
  2. MedlinePlus Genetics (US National Library of Medicine): Parkinson disease
  3. DailyMed (US National Library of Medicine): Vyalev (foscarbidopa/foslevodopa) US prescribing information, version published 9 April 2026
  4. DailyMed (US National Library of Medicine): Nuplazid (pimavanserin tartrate) US prescribing information, version published 22 June 2026
  5. Alamri et al. Parkinson's Disease in the Gulf Countries: An Updated Review. Eur Neurol 2015 (PubMed 26613525)
  6. SFDA: Drugs List, public register (all 9,173 entries checked by brand name on 17 October 2026)
  7. Department of Health Abu Dhabi: drug code list Drugs.xlsx (release 26 September 2026, effective 2 October 2026)
  8. DailyMed (US National Library of Medicine): Crexont (carbidopa and levodopa) US prescribing information, version published 1 June 2026
  9. DailyMed (US National Library of Medicine): Ongentys (opicapone) US prescribing information, version published 17 November 2025
  10. DailyMed (US National Library of Medicine): Xadago (safinamide mesylate) US prescribing information, version published 8 October 2026
  11. DailyMed (US National Library of Medicine): Gocovri (amantadine) US prescribing information, version published 6 October 2026
  12. SFDA: Special Access Program (SAP) guidance, version 1.0
  13. NHRA Bahrain: Circular No. (41) of 2020, procedures for importing non-registered medicines and pharmaceutical products

Related

This page is general health information, not medical advice. It does not replace a consultation with your doctor.

WhatsApp